Organogenesis (ORGO) Set to Announce Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is set to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Organogenesis to post earnings of ($0.03) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Organogenesis Price Performance

Shares of ORGO opened at $2.44 on Wednesday. The firm has a market capitalization of $321.98 million, a PE ratio of 61.02 and a beta of 1.60. The stock’s 50 day moving average is $2.80 and its two-hundred day moving average is $3.09. Organogenesis has a twelve month low of $1.96 and a twelve month high of $4.70. The company has a current ratio of 2.80, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $5.00 price objective on shares of Organogenesis in a research report on Friday, March 1st.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.